161 related articles for article (PubMed ID: 27719744)
1. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.
Frenzel W; Wietek S; Svae TE; Debes A; Svorc D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):847-855. PubMed ID: 27719744
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of the intravenous immunoglobulin octagam
Wietek S; Svorc D; Debes A; Svae TE
Hematology; 2018 May; 23(4):242-247. PubMed ID: 29020871
[TBL] [Abstract][Full Text] [Related]
4. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
Ochs HD; Pinciaro PJ;
J Clin Immunol; 2004 May; 24(3):309-14. PubMed ID: 15114062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
Robak T; Mainau C; Pyringer B; Chojnowski K; Warzocha K; Dmoszynska A; Straub J; Imbach P
Hematology; 2010 Oct; 15(5):351-9. PubMed ID: 20863431
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
7. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
9. Octagam
Wietek S
Neurodegener Dis Manag; 2018 Aug; 8(4):227-231. PubMed ID: 29517417
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin.
Brenner B
Clin Exp Rheumatol; 1996; 14 Suppl 15():S115-9. PubMed ID: 8828958
[TBL] [Abstract][Full Text] [Related]
11. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
[TBL] [Abstract][Full Text] [Related]
12. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
Bauhofer A; Dietrich RL; Schmeidl R
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
15. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.
Spadaro G; Vultaggio A; Alberto Bosi A; Reichert D; Janssen J; Lamacchia D; Nappi L; Pecoraro A; Milito C; Ferraro A; Matucci A; Bacchiarri F; Carrai V; Hibbeler A; Speckman E; Guarnieri C; Bongiovanni S; Quinti I
Int Immunopharmacol; 2017 Mar; 44():38-42. PubMed ID: 28073042
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
17. Gammaplex
Wasserman RL
Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
[TBL] [Abstract][Full Text] [Related]
18. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
19. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
20. The role of intravenous immunoglobulins in pediatric diseases.
Ramasubramanian KV; Kumar A; Kabra SK; Seth V
Indian Pediatr; 1999 Jan; 36(1):51-63. PubMed ID: 10709123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
